Drug Approval | March 25, 2023
Zydus receives final approval from USFDA for Doxepin Hydrochloride Capsules USP, 150 mg
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation)
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Granules now have a total of 53 ANDA approvals from USFDA
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Subscribe To Our Newsletter & Stay Updated
